相关实验视频
Updated: Jul 2, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
肝脏和心血管事件风险的血糖控制目标在与代谢功能障碍相关的脂肪性肝病中
Nobuharu Tamaki1, Shun-Ichi Wakabayashi2, Takefumi Kimura2
1Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
在与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者中,优化血糖控制至关重要. 7%的HbA1c水平被确定为降低肝脏相关事件和主要不良心血管事件 (MACE) 风险的最佳门.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 与肝脏相关和心血管事件的风险增加有关.
- 优化血糖控制是减轻这些风险的潜在策略.
- 精确的血红蛋白A1c (HbA1c) 值对于MASLD患者的风险降低仍然没有定义.
研究的目的:
- 确定最佳的血红蛋白A1c (HbA1c) 值,以尽量减少MASLD患者的肝脏相关事件和主要不良心血管事件 (MACE).
- 调查HbA1c水平与该人群并发症风险之间的剂量依赖关系.
主要方法:
- 全国一项以人口为基础的队列研究包括633,279名患有MASLD的患者.
- 年度HbA1c测量是在平均4.2年的随访期间收集的.
- 主要终点是肝脏相关事件和MACE,并进行统计分析以确定最佳HbA1c值.
主要成果:
- 增加的HbA1c水平显示出剂量依赖的关联与肝脏相关事件和MACE的风险更高.
- 与参考范围 (5.0%-5.9%) 相比,特定的HbA1c范围 (例如,≥9.0%) 显著增加了风险.
- 7%的HbA1c水平被确定为最佳值,与降低风险相关 (肝脏事件的sHR为2.40,MACE为1.98).
结论:
- 血糖控制对于管理MASLD患者至关重要.
- 7%的HbA1c水平是降低肝脏和心血管并发症风险的有效门.
- 针对7%以下的HbA1c可能是MASLD患者的有益策略.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
相关概念视频
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Hypoglycemia and Glucagon